Skip to main content
. 2016 Feb 15;31(2):242–252. doi: 10.3904/kjim.2015.112

Figure 4.

Figure 4.

Subgroup analysis of the overall survival of hepatocellular carcinoma patients undergoing transarterial chemoembolization (TACE) + radiofrequency ablation (RFA), RFA, or TACE according to the main tumor size. (A) There were significant differences in the long-term survival of patients undergoing TACE + RFA in tumors < 3 cm in size compared to patients receiving only RFA or TACE treatment (p = 0.017 and p = 0.004, respectively). (B) Significant differences were not observed in the overall survival benefit of the patients undergoing TACE + RFA in tumors ≥ 3 cm in size compared to patients receiving only RFA or TACE treatment (p = 0.763 and p = 0.952, respectively).